Data / Research funding / Biodefense and Related Countermeasures
Biodefense and Related Countermeasures: 4,709 NIH awards ($10.6B) to 678 organizations
4,709 NIH awards ($10.6B) in the NIH spending category Biodefense and Related Countermeasures, to 678 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 4,709 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $650,978,035 | May 24, 2021 | May 23, 2025 | KATZ, STUART D | reporter.nih.gov |
| Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $472,070,715 | December 1, 2024 | November 30, 2025 | CURRIER, JUDITH S. | reporter.nih.gov |
| HIV Vaccines Clinical Trials Network Leadership and Operations Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $244,071,463 | June 29, 2006 | November 30, 2027 | COREY, LAWRENCE | reporter.nih.gov |
| Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases: Mpox Clinical Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $150,331,625 | March 1, 2021 | February 28, 2026 | EWELL, MARIAN | reporter.nih.gov |
| NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE: AVIAN INFLUENZA RESEARCH | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $91,354,067 | April 1, 2021 | January 14, 2027 | WEBBY, RICHARD | reporter.nih.gov |
| AI-driven Structure-enabled Antiviral Platform (ASAP) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $89,845,851 | May 16, 2022 | August 31, 2027 | CHODERA, JOHN DAMON | reporter.nih.gov |
| CLINICAL RESEARCH OPERATIONS AND MANAGEMENT SUPPORT (CROMS) - SARS CoV-2 Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $86,825,316 | April 17, 2017 | April 16, 2024 | HOLMES, MELYNDA | reporter.nih.gov |
| Statistical and Data Management Center (SDMC), Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $84,840,845 | June 29, 2006 | November 30, 2027 | HUGHES, MICHAEL DAVID | reporter.nih.gov |
| Antibacterial Resistance Leadership Group (ARLG) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $78,031,274 | June 1, 2013 | November 30, 2026 | FOWLER, VANCE G. | reporter.nih.gov |
| IMPAACT Leadership Group | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $77,468,129 | December 1, 2024 | November 30, 2027 | NACHMAN, SHARON A | reporter.nih.gov |
| COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $72,825,966 | September 10, 2019 | September 24, 2026 | KRAMMER, FLORIAN | reporter.nih.gov |
| ANIMAL MODEL DEVELOPMENT AND EFFICACY TESTING OF CANDIDATE MEDICAL COUNTERMEASURES (MCMS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $72,520,576 | September 30, 2025 | September 29, 2026 | reporter.nih.gov | |
| Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $63,155,364 | December 5, 2019 | November 30, 2026 | STEPHENS, DAVID S | reporter.nih.gov |
| Microbiology and Infectious Diseases Biological Resource Repository (MID-BRR) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $63,039,784 | May 5, 2022 | October 31, 2023 | WILLIAMS, CARLA | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $62,580,113 | April 1, 2021 | September 17, 2026 | GARCIA-SASTRE, ADOLFO | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $61,029,344 | September 30, 2019 | March 31, 2027 | URDAHL, KEVIN | reporter.nih.gov |
| SDMC - IMPAACT Leadership Group | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $59,233,299 | June 29, 2006 | November 30, 2027 | SHAPIRO, DAVID ERIC | reporter.nih.gov |
| AIDS Clinical Trial Group Laboratory Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $56,714,107 | January 1, 2014 | November 30, 2027 | ALDROVANDI, GRACE M | reporter.nih.gov |
| CIVIC: University of Georgia Center for Influenza Vaccine Research in High Risk Populations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $53,879,677 | September 10, 2019 | September 9, 2026 | ROSS, TED | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $52,452,735 | September 10, 2019 | September 9, 2026 | MOODY, TONY | reporter.nih.gov |
| Tulane National Primate Research Center | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $52,341,995 | May 9, 1997 | April 30, 2028 | HAMM, L LEE | reporter.nih.gov |
| CEIRR: CORONAVIRUS RESEARCH ACTIVITIES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $50,650,417 | April 1, 2021 | September 29, 2026 | HENSLEY, SCOTT | reporter.nih.gov |
| DMID Clinical Research Operations & Management Support (CROMS): mpox activities | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $47,983,949 | April 1, 2024 | March 31, 2026 | ELLIS, JESSICA | reporter.nih.gov |
| Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $44,959,734 | August 13, 2025 | November 30, 2026 | KOTLOFF, KAREN L. | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component B: Vaccine Manufacturing and Toxicology Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $44,296,051 | August 26, 2019 | March 13, 2028 | DENNY, THOMAS | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $38,435,039 | September 30, 2019 | September 29, 2026 | FORTUNE, SARAH | reporter.nih.gov |
| Vanderbilt Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $36,564,580 | December 11, 2019 | November 30, 2026 | CREECH, CLARENCE BUDDY | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $35,184,139 | August 1, 2021 | July 31, 2026 | COLER, RHEA | reporter.nih.gov |
| DIVINCI: Dissection of Influenza Vaccination and Infection for Childhood Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $30,010,720 | May 2, 2019 | April 30, 2027 | WEBBY, RICHARD JOHN | reporter.nih.gov |
| Task V15: Development of Assays and Reagents for mpox Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $28,751,383 | September 1, 2022 | April 30, 2026 | RUDGE, THOMAS | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response (CEIRR): Avian Influenza Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $27,250,171 | April 1, 2021 | January 14, 2027 | LOWEN, ANICE | reporter.nih.gov |
| Louisiana Clinical and Translational Science Center | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $25,457,946 | August 15, 2012 | June 30, 2027 | KIRWAN, JOHN P. | reporter.nih.gov |
| Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,789,202 | May 15, 2019 | April 30, 2027 | STAAT, MARY A | reporter.nih.gov |
| University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,477,809 | February 1, 2007 | November 30, 2027 | ERON, JOSEPH J | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $23,280,590 | August 1, 2021 | January 14, 2027 | PEKOSZ, ANDREW | reporter.nih.gov |
| Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimer’s disease in Ancestral and Admixed Populations | NIH | National Institute on Aging | 2023 to 2025 | $23,106,653 | August 15, 2023 | July 31, 2028 | DE ERAUSQUIN, GABRIEL ALEJANDRO | reporter.nih.gov |
| Vaccine and Treatment Evaluation Units | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $22,981,366 | December 11, 2019 | November 30, 2026 | ROUPHAEL, NADINE GEORGES | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $21,835,693 | July 1, 2020 | August 31, 2026 | PEVEAR, DANIEL | reporter.nih.gov |
| CENTERS FOR RESEARCH ON STRUCTURAL BIOLOGY OF INFECTIOUS DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $21,661,527 | September 1, 2022 | August 31, 2026 | STAKER, BART | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,625,203 | April 1, 2021 | September 14, 2027 | TOMPKINS, S. MARK | reporter.nih.gov |
| UZ-UCSF CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,624,239 | September 9, 2025 | November 30, 2027 | CHIRENJE, ZVAVAHERA MIKE | reporter.nih.gov |
| UCLA AIDS Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,546,764 | February 1, 2007 | November 30, 2027 | LANDOVITZ, RAPHAEL J | reporter.nih.gov |
| Vaccine and Treatment Evaluation Unit at Saint Louis University | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,219,564 | December 11, 2019 | November 30, 2026 | HOFT, DANIEL F. | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $21,157,224 | July 1, 2020 | January 31, 2025 | CIRZ, RYAN | reporter.nih.gov |
| CENTERS FOR RESEARCH ON STRUCTURAL BIOLOGY OF INFECTIOUS DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $20,695,869 | September 1, 2022 | August 31, 2026 | SATCHELL, KARLA | reporter.nih.gov |
| COVID-19: External Quality Assurance Program Oversight Laboratory (EQAPOL) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $20,632,183 | September 30, 2023 | September 29, 2024 | DENNY, THOMAS | reporter.nih.gov |
| BIOINFORMATICS RESOURCE CENTERS FOR INFECTIOUS DISEASES: SARS-CoV-2 ACTIVITIES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $20,255,157 | September 15, 2019 | September 14, 2024 | STEVENS, RICK | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component C: Clinical Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $19,720,676 | September 16, 2019 | September 15, 2026 | FRANKENFIELD, JILL | reporter.nih.gov |
| ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $18,205,751 | September 19, 2022 | September 18, 2026 | SAUNDERS, KEVIN | reporter.nih.gov |
| UCSD Collaborative Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $18,116,542 | December 1, 2024 | November 30, 2027 | WILKIN, TIMOTHY J. | reporter.nih.gov |
| The Wake Forest Nonhuman Primate Radiation Survivor Cohort | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,517,826 | August 1, 2020 | July 31, 2027 | CLINE, J. MARK | reporter.nih.gov |
| Development of Therapeutic Products for Antibacterial Resistant Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,380,862 | September 9, 2019 | January 31, 2026 | OSCHNER, URS | reporter.nih.gov |
| East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,134,028 | June 1, 2025 | June 30, 2026 | WOOLS-KALOUSTIAN, KARA KAY | reporter.nih.gov |
| Emory-CDC CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,972,899 | December 1, 2024 | November 30, 2027 | KELLEY, COLLEEN F | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component C: Clinical Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,914,921 | September 16, 2019 | September 30, 2026 | BERES, WENDELL | reporter.nih.gov |
| International epidemiology Databases to Evaluate AIDS (IeDEA) Southern Africa. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,840,939 | May 1, 2025 | April 30, 2027 | ROHNER, ELIANE | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $16,069,735 | September 22, 2022 | August 31, 2025 | CIRZ, RYAN | reporter.nih.gov |
| Central Africa International Epidemiology databases to Evaluate AIDS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,957,495 | May 1, 2025 | April 30, 2027 | YOTEBIENG, MARCEL | reporter.nih.gov |
| DEVELOPMENT OF A VACCINE CANDIDATE FOR CORONAVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $15,898,493 | June 1, 2023 | May 31, 2026 | KRAMMER, FLORIAN | reporter.nih.gov |
| C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $15,575,398 | July 1, 2024 | May 31, 2026 | NAHID, PAYAM | reporter.nih.gov |
| Therapeutic Editing to Lower PrP in Prion Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $15,507,691 | May 17, 2023 | April 30, 2026 | VALLABH, SONIA MINIKEL | reporter.nih.gov |
| PERU Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,506,525 | December 1, 2024 | November 30, 2027 | SANCHEZ, JORGE LUIS | reporter.nih.gov |
| Caribbean, Central, and South America network for HIV Epidemiology (CCASAnet) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,404,946 | May 1, 2025 | June 30, 2026 | CASTILHO, JESSICA L | reporter.nih.gov |
| NIAID Influenza Data Processing and Communication Center: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,386,477 | April 1, 2021 | March 31, 2026 | BOUR, STEPHAN | reporter.nih.gov |
| University of Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,173,751 | December 11, 2019 | November 30, 2026 | WALD, ANNA | reporter.nih.gov |
| PHRU-Setshaba Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,110,381 | December 1, 2024 | November 30, 2027 | GRAY, GLENDA E | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $14,810,179 | July 1, 2020 | October 19, 2025 | OCHSNER, URS ARNOLD | reporter.nih.gov |
| CODA: COvid and Diabetes Assessment | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $14,508,027 | July 21, 2023 | June 30, 2028 | ROTHMAN, RUSSELL L. | reporter.nih.gov |
| Task A90: Establishment of a Model of Nipah Virus Infection for Assessment of Medical Countermeasures Efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,497,049 | April 15, 2024 | September 2, 2025 | BEASLEY, DAVID | reporter.nih.gov |
| Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $14,399,999 | March 26, 2024 | February 28, 2029 | SAVIC, RADOJKA | reporter.nih.gov |
| University of Rochester Vaccine and Treatment Evaluation Unit (VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,263,529 | December 11, 2019 | November 30, 2026 | FALSEY, ANN R | reporter.nih.gov |
| 1/2 REPRIEVE Extension for Trial Completion | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $14,219,228 | May 1, 2023 | April 30, 2027 | GRINSPOON, STEVEN K. | reporter.nih.gov |
| Kaiser Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,173,633 | December 11, 2019 | November 30, 2026 | JACKSON, LISA A | reporter.nih.gov |
| HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,518,599 | April 1, 2007 | November 30, 2027 | BEKKER, LINDA-GAIL | reporter.nih.gov |
| Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,340,237 | April 10, 2020 | November 30, 2026 | MULLIGAN, MARK JOSEPH | reporter.nih.gov |
| Vanderbilt HIV Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,733,650 | February 1, 2007 | November 30, 2027 | HAAS, DAVID W | reporter.nih.gov |
| Case Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,725,521 | December 1, 2024 | November 30, 2027 | YENDEWA, GEORGE | reporter.nih.gov |
| RADXHIV VIRAL LOAD | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $12,723,739 | September 11, 2007 | July 31, 2028 | MANABE, YUKARI C | reporter.nih.gov |
| Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,580,221 | June 1, 2025 | May 31, 2027 | SETTE, ALESSANDRO | reporter.nih.gov |
| Development of an Antiviral to Combat Viral Infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $12,480,276 | November 15, 2022 | April 17, 2025 | CHANG, JINHONG | reporter.nih.gov |
| Columbia Collaborative HIV/AIDS Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,286,513 | February 1, 2007 | November 30, 2027 | SOBIESZCZYK, MAGDALENA ELZBIETA | reporter.nih.gov |
| Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,115,898 | December 11, 2019 | November 30, 2026 | FRENCK, ROBERT WILSON | reporter.nih.gov |
| TB-RICC 3.0 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $11,818,694 | April 1, 2023 | March 31, 2028 | ELLNER, JERROLD J. | reporter.nih.gov |
| REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD | NIH | National Institute on Aging | 2024 to 2025 | $11,773,020 | January 1, 2024 | December 31, 2028 | ELY, E WESLEY | reporter.nih.gov |
| Task A71: Comprehensive In Vivo Screening of Viral Pathogens of Pandemic Potential | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,745,278 | July 18, 2022 | July 17, 2025 | MORREY, JOHN | reporter.nih.gov |
| Development of an Optimized Adjuvanted TB Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,645,061 | September 30, 2021 | September 30, 2025 | EVANS, JAY | reporter.nih.gov |
| WaNPRC Macaca nemestrina SPF Breeding Colony | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $11,361,503 | September 30, 2002 | June 30, 2028 | FULLER, DEBORAH H. | reporter.nih.gov |
| West African Emerging Infectious Disease Research Center (WA-EIDRC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,322,650 | May 21, 2020 | June 5, 2025 | ANDERSEN, KRISTIAN GRAUGAARD | reporter.nih.gov |
| KwaZulu-Natal Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,302,268 | December 1, 2024 | November 30, 2027 | ABDOOL KARIM, QUARRAISHA | reporter.nih.gov |
| Clinical Development of COVID-19 Therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $11,286,393 | September 22, 2023 | February 15, 2026 | WANG, STANLEY | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,268,155 | September 1, 2020 | March 31, 2027 | MALINOWSKI, FRANK | reporter.nih.gov |
| Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,202,199 | March 15, 2007 | September 21, 2025 | SANNE, IAN MATTHIAS | reporter.nih.gov |
| Emerging Infectious Diseases Research Centers Coordination Center (EIDRC CC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,018,742 | May 18, 2020 | April 30, 2025 | SEMPOWSKI, GREGORY D | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $10,977,909 | September 21, 2022 | November 8, 2024 | TOMARAS, ANDREW | reporter.nih.gov |
| Advancing Vaccine Adjuvant Research for Tuberculosis (TB) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $10,964,476 | September 30, 2022 | September 29, 2027 | BRITTON, WARWICK | reporter.nih.gov |
| Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,947,708 | February 5, 2007 | November 30, 2027 | GUPTA, AMITA | reporter.nih.gov |
| Advanced Development of a Universal Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,853,574 | September 9, 2019 | April 24, 2025 | LOCHER, CHRISTOPHER | reporter.nih.gov |
| Reagent Program for HIV and other Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,735,388 | October 15, 2023 | January 13, 2024 | RASHID, SUJATHA | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,650,296 | September 9, 2019 | October 31, 2025 | CASPER, COREY | reporter.nih.gov |
| Administrative Supplement Request for 2025 Systems Biology for Infectious Diseases Annual Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,511,156 | August 17, 2018 | May 31, 2028 | KROGAN, NEVAN J | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense, AntiMicrobial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,501,521 | May 17, 2021 | December 31, 2026 | KANE, BRIAN | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,313,540 | September 23, 2016 | March 31, 2026 | HENKEL, TIMOTHY | reporter.nih.gov |
| ADJUVANT COMPARISON AND CHARACTERIZATION | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $10,234,165 | September 1, 2022 | January 1, 2027 | FELGNER, PHILIP | reporter.nih.gov |
| Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,070,868 | March 15, 2007 | November 30, 2027 | SUPPARATPINYO, KHUANCHAI | reporter.nih.gov |
| Advanced Development of Medical Countermeasures for Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,028,832 | September 9, 2019 | August 11, 2024 | TOMIC, MILAN | reporter.nih.gov |
| Advanced Development of a Multivalent Vaccine Candidate for Lassa Fever | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,931,387 | September 1, 2017 | January 31, 2027 | SCHNELL, MATTHIAS JOHANNES | reporter.nih.gov |
| The Military HIV Research Program (MHRP) Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,676 | December 10, 2013 | November 30, 2027 | ROBB, MERLIN L | reporter.nih.gov |
| The Johns Hopkins University - Uganda Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,249 | February 5, 2007 | November 30, 2027 | FOWLER, MARY GLENN | reporter.nih.gov |
| Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,862,919 | March 22, 2022 | February 28, 2027 | FERNANDEZ-SESMA, ANA | reporter.nih.gov |
| Botswana-Harvard T.H. Chan School of Public Health AIDS Initiative Partnership CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,824,534 | February 1, 2007 | June 30, 2025 | LOCKMAN, SHAHIN | reporter.nih.gov |
| Center for Modeling Complex Interactons | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $9,684,540 | March 15, 2015 | June 30, 2025 | WICHMAN, HOLLY A | reporter.nih.gov |
| GHESKIO Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,655,243 | February 1, 2007 | November 30, 2027 | PAPE, JEAN WILLIAM | reporter.nih.gov |
| DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $9,566,206 | September 30, 2023 | September 29, 2026 | EVANS, JAY | reporter.nih.gov |
| University of Washington Arboviral Research Network (UWARN) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $9,499,281 | May 22, 2020 | June 5, 2025 | VAN VOORHIS, WESLEY C | reporter.nih.gov |
| Development of a Novel Therapeutic for Melioidosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,235,577 | September 20, 2022 | September 30, 2026 | ALLEY, M.R.K. (DICKON) | reporter.nih.gov |
| Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,218,182 | August 24, 2022 | July 31, 2027 | BARKER, BRIDGET MARIE | reporter.nih.gov |
| Understanding Risk Gradients from Environment on Native American Child Health Trajectories: Toxicants, Immunomodulation, Metabolic syndromes, & Metals Exposure | NIH | Office of the Director, National Institutes of Health | 2023 to 2024 | $8,902,713 | September 21, 2016 | May 31, 2025 | MACKENZIE, DEBRA | reporter.nih.gov |
| Understanding Risk Gradients from Environment on Native American Child Health Trajectories: Toxicants, Immunomodulation, Metabolic syndromes, & Metals Exposure | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $8,860,022 | September 21, 2016 | May 31, 2030 | MACKENZIE, DEBRA | reporter.nih.gov |
| Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $8,743,439 | September 25, 2023 | June 24, 2024 | RAMSTEDT, URBAN | reporter.nih.gov |
| Task V34: Master Cell Banks Manufacturing for Next Generation SARS-CoV-2 Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $8,647,922 | May 15, 2018 | May 14, 2028 | TRUSHEIM, HEIDI | reporter.nih.gov |
| Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. Coli Infection (HIKO STEC): A Multinational, Embedded, Cluster, Crossover, Randomized Trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,451,589 | September 17, 2021 | August 31, 2027 | FREEDMAN, STEPHEN BRADLEY | reporter.nih.gov |
| The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,239,326 | January 15, 2008 | November 30, 2027 | GRINSZTEJN, BEATRIZ | reporter.nih.gov |
| Hazardous Materials Worker Health and Safety Training (U45), Cooperative Agreement | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $8,171,064 | September 1, 1992 | May 31, 2030 | TURCOTTE, DAVID | reporter.nih.gov |
| A deep longitudinal analysis of next generation influenza vaccines in older adults | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $8,127,184 | January 1, 2022 | December 31, 2026 | UCAR, DUYGU | reporter.nih.gov |
| Human Biomimetics for Mucosal Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,059,968 | March 15, 2015 | May 31, 2027 | ESTES, MARY KOLB | reporter.nih.gov |
| Rutgers University CounterACT Center of Excellence | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2024 | $7,988,704 | September 15, 2006 | August 31, 2025 | LASKIN, JEFFREY D | reporter.nih.gov |
| Advanced Development and Clinical Evaluation of an Entamoeba Histolytica Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $7,788,182 | September 21, 2018 | November 22, 2025 | FOX, CHRISTOPHER | reporter.nih.gov |
| Seattle Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $7,698,581 | February 1, 2007 | November 30, 2027 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| FEND for TB | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,632,771 | June 4, 2020 | May 31, 2026 | ELLNER, JERROLD J. | reporter.nih.gov |
| The International URBAN Alcohol Research Collaboration on HIV/AIDS (ARCH) Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $7,511,308 | September 10, 2021 | August 31, 2027 | SAMET, JEFFREY H. | reporter.nih.gov |
| Advanced Development of Vaccines for Filoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,417,867 | July 21, 2020 | December 31, 2026 | ELDRIDGE, JOHN | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers STATISTICAL, DATA MANAGEMENT AND COORDINATION CENTER (SDMCC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,400,390 | September 30, 2025 | September 29, 2026 | BOUR, STEPHAN | reporter.nih.gov |
| Harmonist: A Scalable Toolkit for Standardizing and Coordinating Data Sharing Across International Research Networks | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,298,694 | May 25, 2016 | April 30, 2027 | DUDA, STEPHANY NORAH | reporter.nih.gov |
| DEVELOPMENT OF VACCINES FOR INFLUENZA USING AN IMMUNO-MODULATOR ADJUVANT AND MULTI-PLATFORM APPROACH | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $7,281,050 | September 30, 2023 | September 29, 2028 | EL-KAMMASH, BRUXANNE | reporter.nih.gov |
| EpiCenter for Emerging Infectious Disease Intelligence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $7,215,074 | July 13, 2020 | June 5, 2025 | JOHNSON, CHRISTINE KREUDER | reporter.nih.gov |
| The Bacterial and Viral Bioinformatics Resource Center (BV-BRC) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $7,200,000 | July 18, 2024 | June 30, 2029 | STEVENS, RICK L. | reporter.nih.gov |
| Adjuvant Development of the TLR4 Ligand BECC470s For Use in Influenza, S. aureus, and P. aeruginosa Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,143,498 | September 30, 2023 | September 29, 2028 | SORENSON, GREGORY | reporter.nih.gov |
| Molecules and Pathways at the Coccidioides Host-Pathogen Interface | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $7,052,234 | January 1, 2022 | December 31, 2026 | SIL, ANITA | reporter.nih.gov |
| TASK ORDER B-15: Model Development and Medical Countermeasure Evaluation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $7,029,612 | October 24, 2022 | October 1, 2023 | GRIFFITHS, ANTHONY | reporter.nih.gov |
| ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,937,118 | September 30, 2023 | September 29, 2026 | COLLINS, NICOLAS | reporter.nih.gov |
| Emerging Infectious Diseases Research Center - East and Central Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,734,930 | June 1, 2020 | June 5, 2025 | NJENGA, M KARIUKI | reporter.nih.gov |
| Emerging infections: surveillance, epidemiology and pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,690,286 | May 11, 2020 | June 5, 2025 | WANG, DAVID | reporter.nih.gov |
| Aurum Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,678,965 | December 1, 2020 | November 30, 2027 | CHURCHYARD, GAVIN JOHN | reporter.nih.gov |
| West African Center for Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,658,566 | June 9, 2020 | June 5, 2025 | WEAVER, SCOTT C | reporter.nih.gov |
| B Cell Epitope Discovery and Mechanisms of Antibody Protection: Responses to Dengue 4, Powassan, Chikungunya, and Venezuelan Equine Encephalitis Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,634,396 | September 16, 2023 | September 15, 2024 | FREMONT, DAVED | reporter.nih.gov |
| GRANEXIN AS A TOPICAL THERAPEUTIC TO MITIGATE CUTANEOUS RADIATION INJURY | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,620,728 | March 16, 2021 | February 28, 2025 | CHATNEKAR, GUATAM | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,612,767 | September 21, 2022 | January 18, 2026 | KRUISWIJK, CORINE | reporter.nih.gov |
| Role of Data Streams In Informing Infection Dynamics in Africa- INFORM Africa | NIH | Fogarty International Center | 2021 to 2025 | $6,610,435 | September 15, 2021 | June 30, 2027 | ABIMIKU, ALASH'LE G. | reporter.nih.gov |
| Leveraging an ongoing longitudinal study of influenza vaccination to define immune signatures of response and risk of infection in older adults >75 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,605,926 | December 9, 2021 | November 30, 2026 | LENG, SEAN XIAO | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,592,393 | September 23, 2022 | July 22, 2026 | NORTON, ELIZABETH | reporter.nih.gov |
| Task A68: Screening Vaccine (and Other Biologics) Platform Technologies using Coronavirus Mouse Immunogenicity as a Model System | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,550,363 | May 23, 2022 | September 30, 2026 | GRAHAM, RACHEL | reporter.nih.gov |
| Stellenbosch University Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,524,563 | April 15, 2007 | November 30, 2027 | HESSELING, ANNEKE CATHARINA | reporter.nih.gov |
| Coordinating Research on Emerging Arboviral Threats Encoing the Neotropics (CREATE-NEO) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,472,246 | June 1, 2020 | June 5, 2025 | VASILAKIS, NIKOS | reporter.nih.gov |
| Small-molecule activators of STING-signaling as novel adjuvants for flavivirus vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,461,817 | September 30, 2019 | September 29, 2024 | NELSON, JAY | reporter.nih.gov |
| METABOLIC ALDEHYDES AS IMMUNE EFFECTORS AGAINST TUBERCULOSIS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,434,161 | September 11, 2025 | August 31, 2029 | DARWIN, KATERINA HERAN | reporter.nih.gov |
| Task A82: Murine Models of UTI Caused by Antibiotic-Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,424,343 | July 19, 2023 | February 27, 2025 | GALLACHER, ANTHONY | reporter.nih.gov |
| Combatting AntiMicrobial Resistance in Africa Using Data Science (CAMRA) | NIH | Fogarty International Center | 2021 to 2025 | $6,419,538 | September 15, 2021 | June 30, 2027 | HAPPI, CHRISTIAN T. | reporter.nih.gov |
| Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,398,428 | July 1, 2021 | June 30, 2027 | GENGENBACHER, MARTIN ALFONS | reporter.nih.gov |
| Protective Genetic Variants for Alzheimer Disease in the Amish - RENEWAL | NIH | National Institute on Aging | 2022 to 2025 | $6,381,039 | September 1, 2022 | May 31, 2027 | HAINES, JONATHAN L | reporter.nih.gov |
| American and Asian Centers for Arboviral Research and Enhanced Surveillance (A2CARES) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,361,142 | July 20, 2020 | May 31, 2025 | HARRIS, EVA | reporter.nih.gov |
| DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,359,752 | September 30, 2023 | September 29, 2028 | LAPEK, JENNIFER | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,358,495 | July 1, 2020 | July 28, 2026 | BOWLIN, TERRY | reporter.nih.gov |
| Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,328,779 | May 4, 2021 | April 30, 2027 | BOYD, STEVEN ARMEN | reporter.nih.gov |
| Mechanisms of Fecal Microbiota Transplant Protection from Recurrent C. difficile | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,326,957 | July 24, 2020 | June 30, 2029 | PETRI, WILLIAM A | reporter.nih.gov |
| Developing Teixobactin for Respiratory Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,154,703 | March 22, 2021 | February 28, 2027 | HUGHES, DALLAS | reporter.nih.gov |
| Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $6,015,134 | September 17, 2021 | August 31, 2025 | DEB, ARJUN | reporter.nih.gov |
| B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,936,710 | September 16, 2019 | August 31, 2025 | CROWE, JAMES E | reporter.nih.gov |
| DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,907,864 | September 30, 2023 | September 29, 2028 | BURKHART, DAVID | reporter.nih.gov |
| Discovery of adjuvants via novel modulation of innate immune pathways for vaccines against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,841,904 | September 30, 2019 | April 30, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| Drivers of individual variation in influenza vaccine response and protection from infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,827,282 | July 14, 2022 | June 30, 2027 | COBEY, SARAH | reporter.nih.gov |
| Critical Factors Influencing Echinocandin Resistance in Candida glabrata | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,673,964 | August 1, 2014 | July 31, 2028 | PERLIN, DAVID S | reporter.nih.gov |
| NBER Center for Aging and Health Research | NIH | National Institute on Aging | 2021 to 2025 | $5,663,258 | August 1, 1997 | August 31, 2027 | CUTLER, DAVID M | reporter.nih.gov |
| Small-molecule inducers of the cGAS/STING pathway as novel adjuvants for flu vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,636,289 | September 30, 2019 | September 29, 2024 | ADOLFO, GARCIA-SASTRE | reporter.nih.gov |
| Task V02: Manufacture of Influenza for Human Challenge Clinical Trials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,587,695 | May 15, 2018 | May 31, 2026 | HASSEL, THOMAS | reporter.nih.gov |
| Exploiting Diversity-Oriented Chemical Synthesis for Combating Chronic Parasitic Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,580,444 | February 8, 2020 | July 31, 2030 | SIBLEY, L. DAVID | reporter.nih.gov |
| Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,559,114 | June 17, 2020 | January 31, 2027 | WALZL, GERHARD | reporter.nih.gov |
| Inter-regional study of transmission, adaptation and pathogenesis of viruses with pandemic potential in Southeast Asia and West/Central Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,526,401 | July 17, 2020 | June 5, 2025 | SAKUNTABHAI, ANAVAJ | reporter.nih.gov |
| Alzheimer’s Disease Related Biomarkers following SARS-CoV-2 Infection | NIH | National Institute on Aging | 2022 to 2025 | $5,518,240 | June 15, 2022 | March 31, 2027 | WISNIEWSKI, THOMAS M | reporter.nih.gov |
| Advanced Development of Vaccines for Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,495,941 | September 9, 2019 | May 31, 2027 | STAERZ, UWE | reporter.nih.gov |
| Small-molecule adjuvants testing pipeline (Influenza) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,486,225 | September 30, 2019 | September 29, 2024 | LEVY, OFER | reporter.nih.gov |
| DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,484,466 | August 21, 2020 | May 31, 2026 | NAHID, PAYAM | reporter.nih.gov |
| IND-Enabling Studies for Arenavirus Preclinical Candidate | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,459,651 | May 13, 2021 | January 31, 2027 | SOKOLOVA, NADEZDA V | reporter.nih.gov |
| Comparative systems biology of apicomplexan cell division | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,447,470 | July 21, 2022 | June 30, 2027 | GUBBELS, MARC-JAN | reporter.nih.gov |
| Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,430,840 | April 12, 2019 | March 31, 2025 | LUETKEMEYER, ANNE FREY | reporter.nih.gov |
| DEVELOPMENT OF IN VITRO DIAGNOSTICS FOR ANTIMICROBIAL RESISTANCE ESCHERICHIA COLI | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $5,422,657 | July 24, 2023 | July 31, 2026 | SAMPATH, RANGARAJAN | reporter.nih.gov |
| Structure-Function Analysis of Mxra8 Interaction with Alphaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,414,348 | June 1, 2019 | July 31, 2029 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Cellular Immunology Core Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $5,413,068 | June 1, 2025 | May 31, 2026 | KAUR, AMITINDER | reporter.nih.gov |
| Developing computational models to predict the immune response to B. pertussis booster vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,401,756 | March 10, 2020 | February 28, 2025 | PETERS, BJOERN | reporter.nih.gov |
| Chicago Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,330,849 | February 1, 2007 | November 30, 2027 | ACHENBACH, CHAD J | reporter.nih.gov |
| Advancement of a poxvirus antiviral | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,192,454 | March 12, 2020 | August 31, 2029 | CONNOR, JOHN H | reporter.nih.gov |
| Development of vaccination strategies to elicit broadly protective immunity against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,165,779 | June 18, 2019 | June 30, 2029 | RAVETCH, JEFFREY VICTOR | reporter.nih.gov |
| Microbial Impact on NeuroDegeneration in Alzheimer's Dementia: MIND-AD | NIH | National Institute on Aging | 2021 to 2025 | $5,121,493 | September 30, 2021 | May 31, 2027 | SPIRA, ADAM PETER | reporter.nih.gov |
| Comparison of High vs. Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,116,475 | June 9, 2023 | March 31, 2028 | HALASA, NATASHA BASSAM | reporter.nih.gov |
| Sialic acid analogs against multidrug-resistant gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,099,184 | April 20, 2021 | March 31, 2027 | RAM, SANJAY | reporter.nih.gov |
| Maternal SARS-CoV-2 infection, placenta biology, and neurodevelopmental outcomes in the offspring | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $5,085,297 | September 5, 2022 | July 31, 2027 | URSINI, GIANLUCA | reporter.nih.gov |
| tRNA in codon usage | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $5,063,701 | March 1, 2020 | August 31, 2029 | HOU, YA-MING | reporter.nih.gov |
| Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2024 | $5,036,160 | September 1, 2022 | August 31, 2027 | CHANG, AILEEN | reporter.nih.gov |
| Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $5,018,496 | July 5, 2023 | May 31, 2028 | VOIGT, EMILY | reporter.nih.gov |
| Quanitifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,011,286 | April 1, 2020 | March 31, 2026 | VAZQUEZ PROKOPEC, GONZALO MARTIN | reporter.nih.gov |
| DEVELOPMENT OF PAN-FILOVIRUS THERAPEUTICS | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,008,204 | November 1, 2022 | March 1, 2027 | BOWLIN, TERRY | reporter.nih.gov |
| The "Dynamics of the immune responses to repeat influenza vaccination exposures" (DRIVE) Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,955,723 | September 11, 2020 | June 30, 2026 | COBEY, SARAH | reporter.nih.gov |
| Bacteriophage-based approach for managing Shigella infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,946,719 | May 5, 2020 | April 30, 2026 | SULAKVELIDZE, ALEXANDER | reporter.nih.gov |
| Preclinical development of a vaccine for Nipah virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,912,518 | March 11, 2021 | February 28, 2027 | GEISBERT, THOMAS WILLIAM | reporter.nih.gov |
| Living in the post-Zika world: Impact of interactions between dengue and Zika viruses on diagnostics, antibody dynamics, and correlates of disease risk | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,905,886 | July 13, 2021 | April 30, 2027 | HARRIS, EVA | reporter.nih.gov |
| Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $4,889,710 | June 7, 2024 | June 1, 2026 | BRUYETTE, DAVID | reporter.nih.gov |
| Large Scale T Cell Epitope Discovery:Global identification of epitopes derived from Zika (ZIKV), Chikungunya (CHIKV) viruses following natural infection and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,881,220 | September 30, 2019 | September 29, 2024 | MITCHELL, MAYA | reporter.nih.gov |
| Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,879,349 | July 1, 2023 | June 30, 2026 | NGUYEN, THERESA | reporter.nih.gov |
| Structure based design of trimer interface epitope focused universal influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,864,362 | March 12, 2020 | February 28, 2025 | CROWE, JAMES E | reporter.nih.gov |
| Deep spatial immune profiling of granulomas and M. tuberculosis adaptation to disease and treatment | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,831,256 | December 1, 2021 | November 30, 2026 | RENGARAJAN, JYOTHI | reporter.nih.gov |
| HIV-1 Fusion Peptide-directed Vaccine Design Using Virus-like Particles | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,825,382 | March 1, 2021 | February 28, 2027 | KONG, RUI | reporter.nih.gov |
| Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,817,583 | September 24, 2021 | August 31, 2024 | RODICK, ROBERT | reporter.nih.gov |
| The economic and social impact of pandemic mitigation policies: A cross-country analysis of macro events | NIH | National Institute on Aging | 2021 to 2025 | $4,809,580 | April 15, 2021 | January 31, 2027 | LILLARD, DEAN R | reporter.nih.gov |
| Novel Stem Cell Immunotherapy for MDR-Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,800,190 | June 4, 2021 | May 31, 2026 | JAGANNATH, CHINNASWAMY | reporter.nih.gov |
| Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,799,861 | September 15, 2020 | August 31, 2025 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Rapid Research for Diagnostics Development in TB Network: Episode 2 (R2D2 TB Network II) | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $4,760,584 | September 23, 2025 | August 31, 2030 | NAHID, PAYAM | reporter.nih.gov |
| Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,757,817 | November 22, 2021 | October 31, 2026 | MARASCO, WAYNE A. | reporter.nih.gov |
| Establishment of a Public-Private Partnership (PPP) to Support Therapy Selection and Testing within RECOVER-TLC | NIH | Office of the Director, National Institutes of Health | 2024 to 2025 | $4,755,161 | September 25, 2024 | December 31, 2026 | PENNINI, MEGHAN | reporter.nih.gov |
| PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,716,636 | May 1, 2025 | April 30, 2027 | KOENIG, SERENA PATRICIA | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,706,565 | September 21, 2022 | April 30, 2027 | THAMMAVONGSA, VILASACK | reporter.nih.gov |
| DEVELOPMENT OF SAPONIN DMLT ADJUVANT (SDA) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,695,387 | September 30, 2023 | September 29, 2026 | NORTON, ELIZABETH | reporter.nih.gov |
| COVID-19 Mother Baby Outcomes (COMBO): brain-behavior functioning | NIH | National Institute of Mental Health | 2021 to 2025 | $4,681,303 | April 12, 2021 | January 31, 2027 | DUMITRIU, DANI | reporter.nih.gov |
| Development and Support of the Pathway Tools Software | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,665,041 | May 12, 2021 | April 30, 2026 | KARP, PETER D | reporter.nih.gov |
| Clinical Trial Site Monitoring for PHOENIx MDR-TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,653,435 | April 15, 2025 | December 14, 2025 | SMITH, KIMBERLY | reporter.nih.gov |
| DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,647,135 | June 29, 2020 | May 31, 2026 | ANTIA, RUSTOM NOSHIR | reporter.nih.gov |
| MYCOBACTERIUM TUBERCULOSIS (MTB) QUALITY ASSESSMENT PROGRAM (TBQA) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,608,548 | January 1, 2023 | December 31, 2023 | COFFIN, JEANETTE | reporter.nih.gov |
| New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,603,680 | September 5, 2019 | August 31, 2025 | DAIGLE, DENIS MARC | reporter.nih.gov |
| A functional evolutionary genetic approach to combat viral infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,591,708 | September 30, 2020 | July 31, 2026 | SCHOGGINS, JOHN W. | reporter.nih.gov |
| Development of In Vitro Diagnostics for the Detection of SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $4,590,862 | June 1, 2023 | May 31, 2025 | SCHAUS, SCOTT | reporter.nih.gov |
| Coordinate Regulation of Virulence in Vibrio Cholerae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,541,366 | July 1, 1981 | March 31, 2029 | MEKALANOS, JOHN JOSEPH | reporter.nih.gov |
| T cell recognition of the MR1 presented microbial metabolome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,523,152 | July 10, 2019 | June 30, 2025 | ADAMS, ERIN JUNE | reporter.nih.gov |
| Development of a handheld rapid air sensing system to monitor and quantify SARS-CoV-2 in aerosols in real-time | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2023 | $4,504,502 | June 1, 2023 | August 31, 2025 | MANCEBO, RICARDO | reporter.nih.gov |
| Impact of tuberculosis on the development and function of the immune system in SIV-infected infants | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $4,476,086 | April 1, 2019 | March 31, 2025 | WANG, XIAOLEI | reporter.nih.gov |
| Understanding Risk of Zoonotic Virus Emergence in EID Hotspots of Southeast Asia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,474,707 | June 17, 2020 | May 15, 2024 | DASZAK, PETER | reporter.nih.gov |
| Discovering antimicrobials acting against MDR pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,469,088 | September 2, 2022 | August 31, 2026 | LEWIS, KIM | reporter.nih.gov |
| DEVELOPMENT OF MYELO001 AS AN ORALLY APPLIED MEDICAL COUNTERMEASURE FOR THE TREATMENT OF HEMATOPOIETIC ACUTE RADIATION SYNDROME | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,444,598 | May 1, 2020 | December 31, 2024 | ERDMANN, TILL | reporter.nih.gov |
| Regulation of Protein C Pathways | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,441,427 | June 1, 2018 | March 31, 2026 | MOSNIER, LAURENT OLIVIER | reporter.nih.gov |
| A systems analysis of drug tolerance in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,414,678 | December 1, 2016 | June 30, 2027 | BALIGA, NITIN S | reporter.nih.gov |
| Molecular Analysis and Lineage Tracing of Influenza-Specific, Lung-Resident Memory B Cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,398,832 | April 7, 2020 | March 31, 2027 | RANDALL, TROY D | reporter.nih.gov |
| Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,354,000 | September 30, 2020 | July 31, 2025 | VEESLER, DAVID | reporter.nih.gov |
| Large Scale T Cell Epitope Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,323,930 | September 29, 2019 | September 29, 2025 | GAGE, KASIA | reporter.nih.gov |
| VACCINES ADJUVANT DEVELOPMENT PROGRAM IN INFECTIOUS AND IMMUNE MEDIATED DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,300,145 | September 30, 2023 | September 29, 2026 | DOWLING, DAVID JAMES | reporter.nih.gov |
| Viral and immune-mediated CNS pathology during SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,269,302 | July 24, 2020 | June 30, 2025 | IWASAKI, AKIKO | reporter.nih.gov |
| Inflammation and Fibrosis in Pulmonary TB: the INFIN-TB Study | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,248,593 | July 1, 2025 | June 30, 2027 | AULD, SARA | reporter.nih.gov |
| Preventing TB with intravenous BCG in SIV-infected macaques | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,248,442 | May 5, 2021 | April 30, 2026 | SCANGA, CHARLES A. | reporter.nih.gov |
| Influenza pathogenesis in pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,248,239 | June 14, 2021 | May 31, 2027 | ADAMS WALDORF, KRISTINA M. | reporter.nih.gov |
| Task C24: Process Optimization and Scale Up of an Antibiotic-Resistant Bacterial Agent | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,247,326 | July 19, 2024 | January 18, 2026 | SCHLAGER, HEIDI | reporter.nih.gov |
| DEVELOPMENT OF ANTICERAMIDE TREATMENT AS A NOVEL MEDICAL COUNTERMEASURE FOR ACUTE EFFECTS OF RADIATION EXPOSURE | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,223,612 | July 1, 2023 | September 30, 2025 | DIMMLER III, CHARLES | reporter.nih.gov |
| Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell Death | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,220,934 | September 25, 2017 | August 31, 2027 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| Targeting innate immune pathways, and inflammatory cell death in cytokine-mediated diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,212,442 | June 15, 2021 | May 31, 2026 | KANNEGANTI, THIRUMALA-DEVI | reporter.nih.gov |
| Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections(AMR), and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $4,211,973 | September 18, 2024 | September 17, 2029 | LENIGK, RALF | reporter.nih.gov |
| The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,208,331 | June 1, 2020 | July 31, 2030 | SESHADRI, CHETAN | reporter.nih.gov |
| The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,204,220 | May 15, 2015 | June 30, 2030 | FLEXNER, CHARLES W. | reporter.nih.gov |
| Capturing spatial patterns of new M. tuberculosis infection in Kampala, Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,188,624 | August 9, 2019 | July 31, 2026 | BARK, CHARLES MARTYN | reporter.nih.gov |
| Structural Analysis and Inhibitor Optimization of Cryptosporidium n-myristoyltransferase for Drug Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,163,372 | November 15, 2020 | October 31, 2026 | STAKER, BART LEE | reporter.nih.gov |
| Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,152,012 | February 1, 2023 | January 31, 2027 | KHADER, SHABAANA A. | reporter.nih.gov |
| Structure and Dynamics of the SARS-CoV-2 Spike Protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,142,443 | July 12, 2021 | June 30, 2027 | MOTHES, WALTHER H | reporter.nih.gov |
| Programmable benchtop bioreactors for scalable eco-evolutionary dynamics of the human microbiome | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,135,886 | June 10, 2022 | May 31, 2027 | KHALIL, AHMAD SAMIR | reporter.nih.gov |
| Longitudinal Study of HIV and Aging in Brazil | NIH | National Institute on Aging | 2021 to 2025 | $4,122,466 | August 15, 2021 | April 30, 2027 | CASTILHO, JESSICA L | reporter.nih.gov |
| Development of mRNA-platform vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,121,318 | January 21, 2021 | December 31, 2026 | DAMRON, FREDRICK HEATH | reporter.nih.gov |
| The role of CD40L in resistance to enteric infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,118,859 | August 17, 2021 | May 31, 2026 | HUNTER, CHRISTOPHER A | reporter.nih.gov |
| Impact of Care Delivery and Therapeutic Changes on Patients with Alzheimer's Disease and Alzheimer's Disease Related Dementias | NIH | National Institute on Aging | 2021 to 2025 | $4,115,749 | September 30, 2021 | May 31, 2027 | HSU, JOHN | reporter.nih.gov |
| A STINGing vaccine for TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,090,805 | June 1, 2020 | May 31, 2026 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Childhood Omics and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis in high HIV prevalence settings | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $4,076,080 | April 22, 2020 | August 31, 2025 | CATTAMANCHI, ADITHYA | reporter.nih.gov |
| Optimization of Lead BKIs for Cryptosporidiosis Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,065,300 | January 1, 2021 | December 31, 2026 | VAN VOORHIS, WESLEY C | reporter.nih.gov |
| Molecular elucidation of the Francisella tularensis virulence mechanism | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,049,782 | May 21, 2021 | April 30, 2027 | SCHUMACHER, MARIA | reporter.nih.gov |
| Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,042,959 | January 25, 2023 | December 31, 2027 | LOUIE, ARNOLD | reporter.nih.gov |
| Structure/Function of Transcription Complex Regulation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,041,062 | July 1, 1987 | August 31, 2027 | LANDICK, ROBERT | reporter.nih.gov |
| The BASIC trial: Improving implementation of evidence-based approaches and surveillance to prevent bacterial transmission and infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,005,071 | June 17, 2021 | May 31, 2027 | BROWN, JEREMIAH R | reporter.nih.gov |
| Investigating Interferon Antagonists in Delaying Innate Immune Responses to SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,981,418 | July 9, 2021 | December 31, 2026 | BAKER, SUSAN C. | reporter.nih.gov |
| Neisseria gonorrhoeae exploits host interferon epsilon to establish infection in the female urogenital tract | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,970,913 | July 1, 2021 | June 30, 2027 | GOLENBOCK, DOUGLAS T | reporter.nih.gov |
| MHC Variation in Host Response to SARS-CoV2 and COVID-19 Outcomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,967,038 | July 13, 2021 | June 30, 2027 | HOLLENBACH, JILL ALLISON | reporter.nih.gov |
| Establishment of a Bat Resource for Infectious Disease Research | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $3,960,972 | September 22, 2023 | August 31, 2028 | SCHOUNTZ, WILLIAM A | reporter.nih.gov |
| Selecting HA glycosylation for improved vaccine responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,957,417 | June 9, 2021 | May 31, 2027 | ZAIA, JOSEPH | reporter.nih.gov |
| Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,954,829 | April 15, 2011 | June 30, 2027 | ICHTCHENKO, KONSTANTIN | reporter.nih.gov |
| Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,950,305 | March 1, 2017 | July 31, 2025 | LIPKA, ELKE | reporter.nih.gov |
| World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,949,988 | February 1, 2016 | March 24, 2025 | WEAVER, SCOTT C | reporter.nih.gov |
| Cryo-EM of Helical Protein and Nucleoprotein Polymers at Near Atomic Resolution | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,949,496 | May 1, 2017 | April 30, 2027 | EGELMAN, EDWARD H. | reporter.nih.gov |
| Optimizing Ridaifen-B analogs as potential therapeutics for Ebola viruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,937,392 | September 20, 2022 | July 31, 2027 | RONG, LIJUN | reporter.nih.gov |
| Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,925,773 | July 1, 2021 | April 30, 2027 | DUNCAN, JOSEPH A | reporter.nih.gov |
| Structure of amyloid fibrils in human neurodegenerative diseases and aging | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $3,924,261 | September 30, 2018 | August 31, 2026 | VIDAL, RUBEN | reporter.nih.gov |
| Next generation mosquito control through technology-driven trap development and artificial intelligence guided detection of mosquito breeding habitats | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,914,766 | September 17, 2021 | August 31, 2026 | NOLAN, MELISSA SUZANNE | reporter.nih.gov |
| Mechanisms of Prion Protein Toxicity | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,903,115 | July 1, 2010 | June 30, 2026 | HARRIS, DAVID A | reporter.nih.gov |
| Understanding Co-morbidities: COVID-19 in individuals living with HIV/AIDS | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,900,756 | February 1, 2022 | January 31, 2027 | SINGH, DHIRAJ KUMAR | reporter.nih.gov |
| Investigating the efficacy and mechanistic pathways of saracatinib, a medical countermeasure, in a pediatric rat DFP model | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,894,577 | August 15, 2021 | July 31, 2027 | THIPPESWAMY, THIMMASETTAPPA | reporter.nih.gov |
| Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,892,523 | August 20, 2021 | July 31, 2025 | AZOITEI, MIHAI LUCHIAN | reporter.nih.gov |
| Discovery of Adjuvants for mRNA Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,882,045 | September 30, 2025 | September 29, 2026 | CARSON, DENNIS | reporter.nih.gov |
| Dietary and synbiotic strategy to limit gut microbiome dysbiosis and protect against Clostridioides difficile infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,880,251 | April 23, 2021 | March 31, 2027 | LOZUPONE, CATHERINE | reporter.nih.gov |
| Carbapenemase-Stable Carbapenem Antibiotics for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,877,163 | April 6, 2021 | March 31, 2027 | VAKULENKO, SERGEI | reporter.nih.gov |
| Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,876,556 | March 15, 2021 | February 28, 2027 | HORWITZ, MARCUS AARON | reporter.nih.gov |
| Cellular and molecular programming of lung resident T cell memory | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,857,630 | May 1, 2020 | April 30, 2027 | KOHLMEIER, JACOB E | reporter.nih.gov |
| Developing broad-spectrum therapeutics against C. difficile toxins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,852,231 | February 11, 2021 | January 31, 2027 | JIN, RONGSHENG | reporter.nih.gov |
| At the Intersection of HIV and COVID-19: Medicaid Data as a Complement to Cohort Studies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,843,434 | June 10, 2022 | May 31, 2027 | LAU, BRYAN | reporter.nih.gov |
| Mechanisms of protection against shigellosis in children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,843,317 | June 9, 2022 | May 31, 2027 | PASETTI, MARCELA F | reporter.nih.gov |
| Skin biomarkers for diagnosing and characterizing AD and ADRD | NIH | National Institute on Aging | 2021 to 2025 | $3,834,262 | September 30, 2021 | June 30, 2027 | KRAUS, ALLISON L | reporter.nih.gov |
| Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,828,356 | September 1, 2021 | August 31, 2026 | GLENN, JEFFREY S | reporter.nih.gov |
| New antifungals targeting the synthesis of fungal sphingolipids | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,827,282 | December 1, 2015 | March 31, 2026 | DEL POETA, MAURIZIO | reporter.nih.gov |
| Identification of novel immunogenic proteins from Bordetella pertussis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,825,567 | June 9, 2021 | May 31, 2027 | DUBEY, PURNIMA | reporter.nih.gov |
| Immune Dysfunction in HIV+ Opioid Users | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,823,539 | April 15, 2020 | January 31, 2027 | PAHWA, SAVITA | reporter.nih.gov |
| Understanding Pandemic Evolution through Networked Data (UPEND) | NIH | National Institute of Mental Health | 2023 | $3,822,251 | April 15, 2023 | April 14, 2026 | CROWELL, TREVOR ADAM | reporter.nih.gov |
| Functional profiling of OSP-specific and other antibodies during shigella infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,818,268 | September 22, 2020 | August 31, 2030 | RYAN, EDWARD T. | reporter.nih.gov |
| Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,809,183 | August 1, 2015 | July 31, 2030 | LARSEN, MICHELLE H | reporter.nih.gov |
| Cell competition in pulmonary fibrosis and ARDS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,796,920 | August 20, 2022 | July 31, 2029 | DE LANGHE, STIJN PIET JOHAN | reporter.nih.gov |
| Task B24: Production of Well Characterized Challenge Material (WCCM) of High Priority Viral Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,793,148 | February 29, 2024 | January 24, 2026 | TAMHANKAR, MANASI | reporter.nih.gov |
| Point-of-care C-reactive protein-based tuberculosis screening in people living with HIV: a randomized trial | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,789,374 | September 15, 2019 | May 31, 2025 | YOON, CHRISTINA | reporter.nih.gov |
| LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,787,436 | July 1, 2021 | June 30, 2027 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Immune response to COVID-19 vaccine in HIV infected men and women | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,779,701 | September 23, 2021 | August 31, 2026 | RINALDO, CHARLES R | reporter.nih.gov |
| Mechanism and Inhibition of SARS-CoV-2 Entry | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,776,105 | July 8, 2021 | June 30, 2026 | WHELAN, SEAN PJ | reporter.nih.gov |
| Genetic Investigation of Covid 19 in Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,774,284 | August 1, 2022 | July 31, 2027 | KAHN, MARK L | reporter.nih.gov |
| O-Specific Polysaccharide Responses and Cholera | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,758,033 | August 7, 2013 | March 31, 2030 | RYAN, EDWARD T. | reporter.nih.gov |
| Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,755,681 | September 17, 2021 | August 31, 2026 | ZANONI, IVAN | reporter.nih.gov |
| Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,749,095 | August 1, 2021 | May 31, 2027 | LUSTIGMAN, SARA | reporter.nih.gov |
| Evolution and inhibition of carbapenemase in beta-lactam resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,748,354 | April 6, 2021 | March 31, 2027 | CHEN, YU | reporter.nih.gov |
| Immunity to Cryptosporidium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,739,027 | January 1, 2020 | December 31, 2029 | HUNTER, CHRISTOPHER A | reporter.nih.gov |
| Validating the Flavivirus Envelope Protein as an Antiviral Target | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,735,490 | March 1, 2020 | February 28, 2026 | YANG, PRISCILLA LI-NING | reporter.nih.gov |
| Sex specific immune response to SARS-CoV-2 leads to chronic neurologic symptoms | NIH | National Institute of Mental Health | 2021 to 2025 | $3,727,455 | September 15, 2021 | July 31, 2026 | MCCULLOUGH, LOUISE D. | reporter.nih.gov |
| Heterosubtypic immunity to influenza virus mediated by MHC-E-restricted memory NK cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,727,019 | September 24, 2021 | August 31, 2027 | JOST, STEPHANIE | reporter.nih.gov |
| Enteric Pathogen Force of Infection among Children using Serology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,719,600 | July 1, 2021 | June 30, 2027 | ARNOLD, BENJAMIN F | reporter.nih.gov |
| Discovery of Adjuvants that Direct T-cell Fates for Improved Safety and Efficacy in Vaccines Against Influenza and Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,714,524 | September 30, 2025 | September 29, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,713,909 | August 21, 2019 | July 31, 2025 | KIRKPATRICK, BETH DIANE | reporter.nih.gov |
| Structure-based design of broad flavivirus immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,710,975 | September 24, 2021 | August 31, 2026 | LAI, JONATHAN R. | reporter.nih.gov |
| Functional B-cell Epitope Discovery for Arthropod-Borne Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,708,329 | September 16, 2024 | September 15, 2027 | reporter.nih.gov | |
| Inborn errors of immunity in patients with life-threatening COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,707,765 | July 12, 2021 | June 30, 2026 | CASANOVA, JEAN-LAURENT | reporter.nih.gov |
| Integrating epidemiologic and environmental approaches to understand and predict Coccidioides exposure and coccidioidomycosis emergence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,707,638 | December 9, 2019 | November 30, 2025 | REMAIS, JUSTIN V | reporter.nih.gov |
| Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,704,381 | March 19, 2021 | February 28, 2027 | AMARASINGHE, GAYA K. | reporter.nih.gov |
| Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,702,250 | April 1, 2024 | March 31, 2025 | MIDDLETON, MARK | reporter.nih.gov |
| Flipped Germinal Centers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,701,340 | September 17, 2021 | August 31, 2026 | WESEMANN, DUANE R. | reporter.nih.gov |
| Research Program Award (R35 Clinical Trial Optional) - Dr. Robyn Klein NINDS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $3,695,974 | May 1, 2021 | October 31, 2024 | CAIN, MATTHEW D | reporter.nih.gov |
| Immunometabolic impact of stress hyperglycemia on tuberculosis treatment outcomes and risk of diabetes mellitus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,694,016 | March 4, 2021 | February 28, 2027 | MAGEE, MATTHEW JAMES | reporter.nih.gov |
| Mtb and HIV/SIV antigen peptide signatures as blood biomarkers to detect early infection to active disease in young children and NHP | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,693,137 | May 1, 2021 | March 31, 2027 | LYON, CHRISTOPHER J | reporter.nih.gov |
| DEVELOPMENT OF ANTIVIRALS FOR SPECIFIC RNA VIRAL FAMILIES OF PANDEMIC POTENTIAL | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $3,692,037 | September 22, 2023 | December 31, 2025 | HENKEL, GREG | reporter.nih.gov |
| Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,690,863 | September 20, 2022 | July 31, 2027 | MELANDER, CHRISTIAN COREY | reporter.nih.gov |
| Understanding the long term impact of COVID-19 on the brain through advanced MR imaging and spectroscopy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,689,933 | July 15, 2021 | June 30, 2026 | OZ, GULIN | reporter.nih.gov |
| Neurodevelopment after postnatal Zika virus infection in infant macaques | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,679,627 | January 1, 2021 | November 30, 2026 | CHAHROUDI, ANN M | reporter.nih.gov |
| Mapping spatiotemporal dynamics during enterovirus infection across cells and tissues | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,677,462 | March 10, 2022 | February 28, 2027 | ANDINO, RAUL | reporter.nih.gov |
| Evaluation of Antibody Responses Elicited by Zika Vaccination in Flavivirus-naïve and -experienced Individuals | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,665,742 | April 13, 2021 | March 31, 2027 | KREBS, SHELLY J | reporter.nih.gov |
| Mapping the genomic and molecular mechanisms of antifungal resistance in the emerging fungal pathogen Candida auris | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,661,637 | March 6, 2023 | February 29, 2028 | ROGERS, P. DAVID | reporter.nih.gov |
| Advancing the development of a novel class of small molecules for treating pan-coronavirus infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,659,295 | August 10, 2021 | July 31, 2027 | EINAV, SHIRIT | reporter.nih.gov |
| PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,656,578 | March 24, 2021 | July 31, 2027 | MACLEOD, IAIN JAMES | reporter.nih.gov |
| The Bring BPaL2Me Trial - Comparing Nurse-Led RR-TB Treatment in Primary Care to Physician-Led, Hospital-Based RR-TB Treatment: A Cluster Randomized, Non-Inferiority Trial | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,655,506 | March 10, 2023 | February 29, 2028 | FARLEY, JASON EDWARD | reporter.nih.gov |
| Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $3,648,087 | September 25, 2021 | August 31, 2025 | GUSTAFSON, DAVID H | reporter.nih.gov |
| Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,639,039 | August 1, 2021 | July 31, 2027 | MOSCONA, ANNE | reporter.nih.gov |
| Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,631,144 | March 4, 2019 | February 28, 2025 | SCANGA, CHARLES A. | reporter.nih.gov |
| Mechanisms of cough in Mycobacterium tuberculosis transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,611,276 | March 8, 2021 | February 28, 2026 | SHILOH, MICHAEL | reporter.nih.gov |
| Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,610,454 | August 5, 2021 | July 31, 2025 | RENGARAJAN, JYOTHI | reporter.nih.gov |
| DEVELOPMENT OF A VACCINE CANDIDATE FOR DRUG-RESISTANT FUNGAL INFECTIONS | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,605,418 | September 30, 2025 | June 1, 2030 | NABORS, GARY | reporter.nih.gov |
| Fusion inhibitors that block host-to-host transmission of SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,603,355 | August 1, 2021 | July 31, 2027 | POROTTO, MATTEO | reporter.nih.gov |
| Development of ureadepsipetides for drug-resistant infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,597,406 | December 17, 2018 | November 30, 2024 | LAFLEUR, MICHAEL | reporter.nih.gov |
| Mechanistic registry to study whether infection with Corona Virus Disease 2019 (COVID-19) accelerates atherosclerotic plaque progression | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,595,504 | February 1, 2022 | June 30, 2026 | SHAW, LESLEE J | reporter.nih.gov |
| Molecular Analysis of Host Immune Response in Leprosy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,593,035 | January 1, 1991 | May 31, 2029 | MODLIN, ROBERT L | reporter.nih.gov |
| Development of a Replicon RNA-based Vaccine against Dengue and Zika | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,590,945 | June 1, 2021 | May 31, 2026 | SHRESTA, SUJAN | reporter.nih.gov |
| Sample-to-Answer, Rapid, Multiplexed and PCR-Free Diagnostics of Arboviral Diseases in Resource Limited Settings | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,579,220 | December 23, 2020 | November 30, 2026 | YANIK, AHMET ALI | reporter.nih.gov |
| Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,575,135 | December 24, 2018 | November 30, 2024 | BRANCO, LUIS MANUEL | reporter.nih.gov |
| Computational and Biophysical Analysis of the Filovirus Matrix Protein System | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,559,101 | August 1, 2021 | July 31, 2026 | STAHELIN, ROBERT VIRGIL | reporter.nih.gov |
| Novel mechanisms regulating immunity to respiratory virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,546,288 | August 2, 2023 | July 31, 2027 | PAUST, SILKE | reporter.nih.gov |
| Chronic Wasting Disease Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,544,335 | July 8, 2021 | June 30, 2027 | MATHIASON, CANDACE K. | reporter.nih.gov |
| The generation and protective function of lung tissue resident memory T cells following SARS-CoV-2 infection or vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,543,436 | March 1, 2022 | February 28, 2027 | TEIJARO, JOHN ROSS | reporter.nih.gov |
| Biophysical studies of macromolecules and molecular assemblies | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,542,462 | July 1, 2016 | July 31, 2026 | BOXER, STEVEN G. | reporter.nih.gov |
| Defining the cell and molecular basis of Toxoplasma recrudescence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,537,428 | January 15, 2021 | December 31, 2025 | WILSON, EMMA H | reporter.nih.gov |
| Genetic, structural and functional profiling of the human antibody response to arenavirus infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,529,436 | August 22, 2022 | July 31, 2027 | BRINEY, BRYAN | reporter.nih.gov |
| Defining adaptive immune responses to Mtb-infection and TB disease among young children with and without HIV-exposure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,527,794 | April 15, 2021 | March 31, 2027 | LANCIONI, CHRISTINA LOUISE | reporter.nih.gov |
| Development of anti-LPS therapeutic antibodies for the treatment of Pseudomonas aeruginosa infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,521,872 | August 1, 2024 | July 31, 2029 | BARBIER, MARIETTE | reporter.nih.gov |
| Combination nanovaccine-based immunization against influenza virus in the aged: immunity and protection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,518,508 | February 16, 2021 | January 31, 2027 | KOHUT, MARIAN L | reporter.nih.gov |
| Impact of the COVID-19 pandemic on patient outcomes, telehealth care delivery, and treatment for unhealthy alcohol use in vulnerable patients with advanced liver disease across two healthcare systems | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $3,517,747 | June 1, 2021 | February 28, 2027 | KHALILI, MANDANA | reporter.nih.gov |
| Optimization of Substituted Phenoxyalkyl Pyridinium Oximes as Therapies for Organophosphate Poisoning | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,512,022 | August 1, 2021 | July 31, 2026 | CHAMBERS, JANICE ELAINE | reporter.nih.gov |
| Host-pathogen interactions in experimental cholera | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,506,027 | January 1, 1998 | May 31, 2027 | WALDOR, MATTHEW K | reporter.nih.gov |
| De Novo Design of Minibinder Antagonists for COVID-19 and Future Pandemics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,504,899 | August 2, 2021 | July 31, 2026 | BAKER, DAVID | reporter.nih.gov |
| The Tick Immune Response During Microbial Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,501,084 | December 1, 2015 | May 31, 2027 | PEDRA, JOAO | reporter.nih.gov |
| Analysis of the Metabolic Capabilities of Prokaryotic Cells | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,499,962 | March 1, 2019 | March 31, 2029 | ESCALANTE, JORGE C | reporter.nih.gov |
| THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,499,688 | July 1, 2023 | June 30, 2026 | HART, BARRY | reporter.nih.gov |
| Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,492,579 | August 1, 2020 | May 31, 2026 | CHAISSON, RICHARD E. | reporter.nih.gov |
| V-OLA point-of-care HIV viral load monitoring and drug resistance testing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,486,755 | June 14, 2019 | April 30, 2029 | LUTZ, BARRY RYAN | reporter.nih.gov |
| Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,479,164 | February 17, 2016 | April 30, 2027 | SURESH, MARULASIDDAPPA | reporter.nih.gov |
| Cerebrospinal fluid (CSF) and peripheral markers of the neuropsychiatric sequelae of COVID-19: The Generation C-SF pregnancy study | NIH | National Institute of Mental Health | 2022 to 2025 | $3,477,672 | April 1, 2022 | January 31, 2027 | PEREZ RODRIGUEZ, MARIA DE LAS MERCEDES | reporter.nih.gov |
| Evaluation of Memory Responses and Biomarkers from a Phase IEnterotoxigenic Escherichia coli (ETEC) Intramuscular SubunitVaccine with dmLT Adjuvant | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,467,638 | September 24, 2021 | August 31, 2026 | NORTON, ELIZABETH B | reporter.nih.gov |
| Host-mediated zinc sequestration during Acinetobacter baumannii infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,464,931 | January 15, 2013 | March 31, 2028 | SKAAR, ERIC P | reporter.nih.gov |
| Neisseria gonorrhoeae metal transporters that subvert nutritional immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,458,371 | August 9, 2017 | July 31, 2027 | CORNELISSEN, CYNTHIA N | reporter.nih.gov |
| Innate Immune Defense Mechanisms in the Intestine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,458,283 | August 1, 2014 | November 30, 2026 | REINECKER, HANS-CHRISTIAN | reporter.nih.gov |
| Rickettsia-host interface and multiple paths to invasion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,450,818 | June 15, 2016 | May 31, 2027 | RAHMAN, MOHAMMED SAYEEDUR | reporter.nih.gov |
| Vibrio cholerae quorum sensing as an intestinal symbiosis factor in a model arthropod host | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,444,100 | June 1, 2021 | June 8, 2026 | WATNICK, PAULA I | reporter.nih.gov |
| Development of MecVax, a Cross Protective Subunit Vaccine for ETEC | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,440,502 | June 1, 2023 | May 31, 2028 | ZHANG, WEIPING | reporter.nih.gov |
| Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,438,006 | April 23, 2021 | March 31, 2027 | TEYTON, LUC | reporter.nih.gov |
| Targeting TB transmission hotspots to find undiagnosed TB in South Africa: a genomic, geospatial and modeling study (TARGET- TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,433,190 | May 1, 2025 | April 30, 2027 | MATHEMA, BARUN | reporter.nih.gov |
| Deciphering the relationship between structure, dynamics and function in helical bundle proteins | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,428,074 | May 1, 2017 | July 31, 2027 | DEGRADO, WILLIAM | reporter.nih.gov |
| Characteristics of Botulinum Neurotoxins the Determine Potency | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,427,741 | January 18, 2019 | June 30, 2029 | PELLETT, SABINE | reporter.nih.gov |
| Unraveling yellow fever 17D vaccine attenuation: The role of type I interferon and innate immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,421,854 | February 15, 2016 | July 31, 2027 | RICE, CHARLES M | reporter.nih.gov |
| Tracking longitudinal change in presymptomatic genetic prion disease (TLC-Pre-gPrD) | NIH | National Institute on Aging | 2021 to 2023 | $3,419,291 | August 1, 2019 | May 31, 2025 | GESCHWIND, MICHAEL D | reporter.nih.gov |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING STUDY TO COMPARE THE SAFETY AND EFFICACY OF 3 DOSE LEVELS OF AV-1 IN HEALTHY ADULTS CHALLENGED WITH A CONTROLLED HUMAN INFECTION S | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $3,418,636 | August 23, 2023 | July 22, 2025 | DURBIN, ANNA PALMER | reporter.nih.gov |
| Multi-Dimensional Outcome Prediction Algorithm for Hospitalized COVID-19 Patients | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,417,860 | July 8, 2021 | June 30, 2027 | DENG, MARIO C. | reporter.nih.gov |
| Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,410,042 | February 21, 2019 | January 31, 2025 | PERLIN, DAVID S | reporter.nih.gov |
| Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,407,387 | January 7, 2019 | December 31, 2023 | GARCIA-SASTRE, ADOLFO | reporter.nih.gov |
| Immunobiology of Influenza Virus-related Critical Illness in Young Hosts | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,406,427 | September 18, 2020 | August 31, 2025 | RANDOLPH, ADRIENNE G | reporter.nih.gov |
| Microbial Community Disruption Following Topical Antimicrobial Application in Staphylococcus aureus-Affected Households | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,400,860 | May 19, 2021 | April 30, 2027 | FRITZ, STEPHANIE ANN | reporter.nih.gov |
| Mycobacterium Tuberculosis (MTB) Quality Assessment Program (TBQA) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,397,377 | November 17, 2024 | November 16, 2025 | OLINGER, GENE GARRARD | reporter.nih.gov |
| Characterizing Vancomycin-Resistant C. difficile Strains at Two Geographically Distinct Locations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,395,135 | April 1, 2021 | March 31, 2027 | DARKOH, CHARLES | reporter.nih.gov |
| Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,379,247 | August 1, 2019 | July 31, 2025 | GREENBERG, DAVID ELIHU | reporter.nih.gov |
| Community-Centered Interventions for Improved Vaccine Uptake for COVID (CIVIC) | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $3,378,034 | April 26, 2021 | May 9, 2025 | MARSH, ERICA E | reporter.nih.gov |
| Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,375,497 | February 18, 2022 | January 31, 2027 | HALASA, NATASHA BASSAM | reporter.nih.gov |
| Inhalation Therapy Platform for Coronavirus Infection Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,373,230 | September 17, 2021 | August 31, 2026 | STAYTON, PATRICK S. | reporter.nih.gov |
| Commensal control of C. difficile virulence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,372,908 | February 1, 2021 | January 31, 2027 | BRY, LYNN | reporter.nih.gov |
| Socio-spatial Networks and Tuberculosis Infection in Youth in Rural Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,369,946 | November 16, 2020 | October 31, 2026 | MARQUEZ, CARINA | reporter.nih.gov |
| Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,356,811 | August 8, 2022 | July 31, 2026 | WANG, LAURENE | reporter.nih.gov |
| Cardiac Magnetic Resonance for Tissue Characterization Based Risk Stratification of Cardiopulmonary Symptoms, Effort Tolerance, and Prognosis Among COVID-19 Survivors | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,354,566 | September 1, 2021 | July 31, 2027 | KIM, JIWON | reporter.nih.gov |
| Developing Inhibitors of Seasonal and Pandemic Influenza Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,352,410 | August 18, 2025 | July 31, 2029 | PLEMPER, RICHARD K. | reporter.nih.gov |
| Mechanisms of Mutant Prion Protein Aggregation Within Endolysosomal Pathways | NIH | National Institute on Aging | 2022 to 2025 | $3,350,798 | May 15, 2022 | April 30, 2027 | ENCALADA, SANDRA E | reporter.nih.gov |
| Targeting Clostridioides difficile with microbiome-sparing, resistant-proof anti-toxins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,343,705 | April 1, 2021 | March 31, 2026 | SCHRAMM, VERN L. | reporter.nih.gov |
| Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,343,171 | January 9, 2019 | December 31, 2024 | IBRAHIM, ASHRAF S. | reporter.nih.gov |
| Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,332,208 | December 14, 2018 | November 30, 2024 | TING, JENNY P | reporter.nih.gov |
| Bumped-Kinase Inhibitor Drug Development for Toxoplasmosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,328,490 | March 15, 2021 | February 28, 2027 | VAN VOORHIS, WESLEY C | reporter.nih.gov |
| M. tuberculosis exosome detection for pediatric TB diagnosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,323,600 | June 1, 2025 | May 31, 2027 | LACOURSE, SYLVIA | reporter.nih.gov |
| TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,322,837 | August 1, 2021 | July 31, 2026 | BOULWARE, DAVID R | reporter.nih.gov |
| Development of Therapeutic Candidates for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,318,955 | September 24, 2025 | February 7, 2029 | KIM, PAUL JOON | reporter.nih.gov |
| ncRNA: structure, function and inhibition | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,317,990 | April 1, 2018 | May 31, 2028 | VARANI, GABRIELE | reporter.nih.gov |
| Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,315,958 | January 1, 2019 | December 31, 2023 | AMBERG, SEAN M | reporter.nih.gov |
| Bacteria and Host in TB Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,309,466 | April 10, 2020 | March 31, 2026 | ALLAND, DAVID | reporter.nih.gov |
| Targeted Delivery of Therapeutics into Motor Neurons for Post-exposure Treatment of Botulism | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,307,348 | August 1, 2021 | July 31, 2027 | DONG, MIN | reporter.nih.gov |
| Lesion-centric optimization of multidrug therapies for tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,301,434 | January 15, 2020 | December 31, 2025 | ALDRIDGE, BREE BEARDSLEY | reporter.nih.gov |
| SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,300,000 | August 17, 2023 | July 31, 2026 | ALPERT, MICHAEL DAVID | reporter.nih.gov |
| Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,297,972 | April 2, 2021 | April 30, 2026 | RONG, LIJUN | reporter.nih.gov |
| Small molecule-induced degradation of dengue proteins as an antiviral strategy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,293,894 | July 23, 2020 | June 30, 2025 | YANG, PRISCILLA LI-NING | reporter.nih.gov |
| Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,293,620 | September 1, 2020 | June 30, 2025 | HALASA, NATASHA BASSAM | reporter.nih.gov |
| B cell Epitope Discovery and Mechanisms of Antibody Protection for Enterovirus and Bunyavirus Entry Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,291,808 | September 16, 2024 | September 15, 2026 | reporter.nih.gov | |
| Hybrid Methods for Dynamic Structure Analysis of Proteins from Pathogenic Microorganisms | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,290,000 | July 1, 2021 | April 30, 2027 | MONTELIONE, GAETANO T | reporter.nih.gov |
| Antibiotics : Studies on the Biological Mechanisms of Antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,289,320 | August 5, 2025 | July 31, 2030 | KAHNE, DANIEL | reporter.nih.gov |
| Role of Ubiquitin Ligases and Deubiquitinases in Host Defense against Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,278,392 | August 21, 2025 | July 31, 2029 | SHILOH, MICHAEL | reporter.nih.gov |
| Diet transformation by the microbiome and its impact on bacterial infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,277,659 | August 16, 2022 | May 31, 2027 | GOODMAN, ANDREW L | reporter.nih.gov |
| Insight into the Ebola virus glycoprotein fusion mechanism gleaned from the 2013-2016 epidemic GP-A82V variant | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,277,276 | January 2, 2020 | December 31, 2025 | LUBAN, JEREMY | reporter.nih.gov |
| MITIGATION OF MULTI-ORGAN DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE (DEARE) WITH ACE-INHIBITOR LISINOPRIL | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,275,826 | July 1, 2023 | June 30, 2026 | LANDRUM, JILL | reporter.nih.gov |
| Temporal Phenotypes and Risk Models for the Post-COVID Syndrome and its sub-types | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,271,583 | July 15, 2022 | June 30, 2027 | ESTIRI, HOSSEIN | reporter.nih.gov |
| Genomic Epidemiology of Campylobacter to Improve Disease Control in Low and Middle Income Countries | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,270,801 | March 15, 2021 | February 28, 2027 | KOSEK, MARGARET N | reporter.nih.gov |
| Broad-spectrum therapeutics against SARS-CoV-2 3CL protease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,268,877 | August 19, 2021 | July 31, 2026 | SCHINAZI, RAYMOND FELIX | reporter.nih.gov |
| Advanced Development of a Combined Shigella-ETEC Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,267,570 | June 9, 2023 | May 31, 2028 | BARRY, EILEEN M. | reporter.nih.gov |
| Development and maintenance of chronic toxoplasmosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,264,053 | March 17, 2021 | February 28, 2027 | LOURIDO, SEBASTIAN | reporter.nih.gov |
| Informing Drug Synergy: Investigating Mycobacterial Membrane Protein Structure and Function | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,262,539 | August 1, 2025 | July 31, 2029 | REGO, ELIZABETH HESPER | reporter.nih.gov |
| Human mobility models to forecast disease dynamics and the effectiveness of public health interventions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,257,651 | April 9, 2021 | March 31, 2027 | WESOLOWSKI, AMY | reporter.nih.gov |
| Programming Durable Immune Responses To Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,255,877 | December 18, 2018 | December 31, 2028 | ELLEBEDY, ALI HASSAN | reporter.nih.gov |
| Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,255,352 | September 16, 2020 | August 31, 2025 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Engineering the Skin Immune System to Induce Systemic Immune Responses | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,251,899 | March 4, 2021 | January 31, 2027 | FALO, LOUIS D | reporter.nih.gov |
| Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,249,590 | March 10, 2020 | February 28, 2026 | SHERMAN, DAVID R | reporter.nih.gov |
| Vaccine-mediated cross-alphavirus protection for a live attenuated FDA licensed chikungunya virus vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,248,576 | July 25, 2025 | June 30, 2029 | COFFEY, LARK L | reporter.nih.gov |
| Human Monoclonal Antibodies for Encephalitic Alphaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,248,015 | July 20, 2022 | June 30, 2027 | CROWE, JAMES E | reporter.nih.gov |
| Video DOT and Economic Incentives to promote adherence to LTBI therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,246,780 | July 8, 2021 | June 30, 2027 | SHAH, MAUNANK | reporter.nih.gov |
| Evolution of T cell immunity in blood and tissues over childhood | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,243,813 | March 16, 2022 | February 28, 2027 | FARBER, DONNA L. | reporter.nih.gov |
| Mechanisms and functions of host organelle usurpation by intravacuolar Toxoplasma | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,239,491 | June 20, 2022 | May 31, 2027 | COPPENS, ISABELLE | reporter.nih.gov |
| PROgression of Tuberculosis infECTion in young children living with and without HIV: the PROTECT study | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,235,332 | April 1, 2023 | March 31, 2028 | CATTAMANCHI, ADITHYA | reporter.nih.gov |
| Leveraging Longitudinal Survey and EHR data to Dissect the Impact of COVID-19 related Stressors and Infections on Child Mental Health and Suicide Risks | NIH | National Institute of Mental Health | 2023 | $3,231,590 | September 1, 2023 | August 31, 2026 | XIAO, YUNYU | reporter.nih.gov |
| Genetic and Structural Basis for Virus Neutralization of Paramyxoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,230,785 | September 16, 2024 | September 15, 2027 | reporter.nih.gov | |
| Dissemination and Implementation of COVID-19 Care Innovations in ED Settings | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,230,156 | March 4, 2022 | February 28, 2026 | MENDEL, PETER JAMES | reporter.nih.gov |
| Novel Methods to Inform HIV/TB Clinical Trial Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,228,180 | September 1, 2011 | August 31, 2025 | REDDY, KRISHNA P | reporter.nih.gov |
| Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,220,673 | August 20, 2018 | January 31, 2028 | HURDLE, JULIAN G | reporter.nih.gov |
| A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,217,894 | August 4, 2023 | July 31, 2027 | SHOEMAKER, CHARLES BIX | reporter.nih.gov |
| Gut Microbiota Modulation of Chikungunya Virus Infection and Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,216,725 | April 1, 2021 | March 31, 2027 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Real-Time Detection of Staphylococcus aureus Transmission in Hospital Settings | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,210,845 | July 25, 2025 | June 30, 2029 | SHOPSIN, BO | reporter.nih.gov |
| Exploitation of multiple heteroresistance for effective antibiotic combination therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,205,931 | July 1, 2020 | June 30, 2026 | WEISS, DAVID S | reporter.nih.gov |
| Identification of Novel Syk/Raf-1 Mediated CLR Ligands as Vaccine Adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,198,798 | September 30, 2025 | September 29, 2026 | EVANS, JAY | reporter.nih.gov |
| The impact of non-dysentery Shigella-associated diarrhea in children | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,197,662 | March 9, 2021 | February 28, 2027 | CHAKRABORTY, SUBHRA | reporter.nih.gov |
| Roles and regulation of tissue resident CD8 T cells during a persistent viral infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,194,992 | July 16, 2025 | June 30, 2029 | ZUNIGA, ELINA I | reporter.nih.gov |
| Dual Targeting of Mtb Resistance Mechanisms | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,194,513 | September 22, 2020 | August 31, 2025 | GRUNDNER, CHRISTOPH | reporter.nih.gov |
| Host Responses to the Pore-Forming Toxin Listeriolysin O | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,191,205 | April 1, 2021 | March 31, 2027 | SEVEAU, STEPHANIE M M | reporter.nih.gov |
| Alanyl-glutamine supplementation of standard treatment for C. difficile infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,184,912 | July 13, 2020 | June 30, 2026 | WARREN, CIRLE ALCANTARA | reporter.nih.gov |
| Developing a bioprinted ventilated lung alveolar platform for investigating microbial interactions and influenza response | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,182,827 | August 19, 2025 | July 31, 2029 | OH, JULIA | reporter.nih.gov |
| Elucidating the path to type I IFNs in TB infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,182,185 | April 1, 2021 | March 31, 2026 | BARCZAK, AMY K | reporter.nih.gov |
| To Develop and Manufacture an Inactivated SARS-CoV-2 Vaccine Using Blood Pathogen Reduction Technology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,181,780 | September 1, 2020 | April 30, 2026 | GOODRICH, RAYMOND | reporter.nih.gov |
| An Enhanced Package of Care to Reduce Mortality in Persons with Advanced HIV Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,179,431 | August 23, 2021 | July 31, 2026 | RAJASINGHAM, RADHA | reporter.nih.gov |
| Biomarker Signatures of TB Infection in Young Children With and Without HIV | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,173,148 | April 28, 2023 | March 31, 2028 | SALGAME, PADMINI | reporter.nih.gov |
| Preclinical modeling to study Tuberculous Meningitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,172,738 | April 1, 2020 | March 31, 2026 | JAIN, SANJAY | reporter.nih.gov |
| Targeted Gene Delivery Systems Treating Lung Diseases | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,172,072 | June 15, 2022 | May 31, 2026 | TIRRELL, MATTHEW | reporter.nih.gov |
| Development and optimization of a peptide inhibitor of influenza virus splicing for broad-spectrum antiviral therapy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,170,096 | August 1, 2025 | July 31, 2029 | TENOEVER, BENJAMIN R. | reporter.nih.gov |
| Rational development of a vaccine against tick-borne rickettsioses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,166,318 | August 1, 2022 | July 31, 2027 | FANG, RONG MEGAN | reporter.nih.gov |
| Development of peptide nucleic acid antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,164,488 | February 10, 2021 | January 31, 2025 | ARYA, DEV PRIYA | reporter.nih.gov |
| Role of Intestinal Parasites on Regulating Immune Responses to Gut Antigens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,164,043 | June 22, 2022 | May 31, 2027 | EDELSON, BRIAN TODD | reporter.nih.gov |
| Transmission dynamics and fitness of reemerging St. Louis encephalitis virus in mosquito vectors and West Nile virus naïve and immune avian reservoirs | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,161,373 | July 22, 2025 | June 30, 2029 | COFFEY, LARK L | reporter.nih.gov |
| Mechanism-based Targeting of the RNA Processing Machinery of SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,161,127 | August 1, 2021 | July 31, 2027 | GUPTA, YOGESH K | reporter.nih.gov |
| Early life B cell responses and inflammation following SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,160,521 | September 17, 2021 | August 31, 2026 | FOUDA AMOU OU, GENEVIEVE GINY | reporter.nih.gov |
| Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,153,952 | September 1, 2013 | May 31, 2029 | BOULWARE, DAVID R | reporter.nih.gov |
| Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,153,883 | September 24, 2018 | October 31, 2028 | HEYSELL, SCOTT K | reporter.nih.gov |
| Dynamics and mechanisms of filovirus envelop glycoproteins | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,151,198 | September 19, 2022 | July 31, 2027 | MUNRO, JAMES B | reporter.nih.gov |
| Dendritic cell intrinsic UPR is critical for pathogen specific Th17 responses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,147,392 | September 1, 2025 | August 31, 2029 | PASARE, CHANDRASHEKHAR | reporter.nih.gov |
| Macrophage senescence as a driver of granuloma failure and progression to necrosis in TB and TB/HIV | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,145,850 | September 19, 2025 | August 31, 2029 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Vibrio cholerae antinitrosative stress defenses and gut microbiome interaction | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,145,639 | September 23, 2020 | August 31, 2025 | ZHU, JUN | reporter.nih.gov |
| Analysis of a novel Crimean-Congo hemorrhagic fever vaccine and its mechanism of protection in rodent models | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,145,040 | August 25, 2022 | July 31, 2026 | SCHNELL, MATTHIAS JOHANNES | reporter.nih.gov |
| Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $3,140,852 | September 10, 2020 | August 31, 2025 | ATHAR, MOHAMMAD | reporter.nih.gov |
| Vesicle-mediated drug resistance of Candida albicans biofilm | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,140,049 | June 15, 2008 | August 31, 2029 | ANDES, DAVID R | reporter.nih.gov |
| Multiplexed Antigen-Specific Antibody Fc Profiling on a Chip for Point-of-Care Diagnosis of TB in HIV-infected Children | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,139,781 | May 6, 2020 | April 30, 2026 | BRYSON, BRYAN DAVID | reporter.nih.gov |
| Mechanisms of atherosclerotic cardiovascular complications | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,139,538 | September 1, 2022 | August 31, 2026 | GIANNARELLI, CHIARA | reporter.nih.gov |
| Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,138,902 | March 5, 2021 | February 28, 2026 | SHRESTA, SUJAN | reporter.nih.gov |
| Discovery of Phospopantetheinyl Transferse Inhibitors Against Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,136,573 | July 13, 2021 | June 30, 2025 | AUBE, JEFFREY | reporter.nih.gov |
| Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,135,970 | February 1, 2019 | January 31, 2029 | DIEHL, SEAN A. | reporter.nih.gov |
| Transport Mechanisms and Inhibition of Efflux Pumps in Pathogenic Organisms | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,135,598 | December 1, 2021 | August 3, 2025 | TRAASETH, NATHANIEL J. | reporter.nih.gov |
| Genomics-Assisted Antibiotic Discovery from Unprecedented Microbes of the Great Salt Lake | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,135,301 | July 12, 2021 | April 30, 2027 | WINTER, JACLYN MARIE | reporter.nih.gov |
| Shigella Conjugate Vaccine (SCV4) Development, Characterization, and Pre-clinical Evaluation | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,134,727 | June 23, 2023 | May 31, 2028 | RYAN, EDWARD T. | reporter.nih.gov |
| Neuronal Latency and Toxoplasma | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,134,435 | September 23, 2020 | August 31, 2025 | HUNTER, CHRISTOPHER A | reporter.nih.gov |
| B-Cell Epitope Discovery and Mechanisms of Antibody Protection for ZIKV, MARV, VEEV Envelope Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,133,973 | September 16, 2019 | September 15, 2024 | DORANZ, BENJAMIN | reporter.nih.gov |
| Iron independent role for yersiniabactin in Yersinia pestis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,128,137 | June 4, 2021 | May 31, 2027 | LAWRENZ, MATTHEW B | reporter.nih.gov |
| Molecular mechanisms driving the coevolution of clinical isolates of phages and epidemic Vibrio cholerae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,128,015 | June 1, 2020 | May 31, 2030 | SEED, KIMBERLEY DIANE | reporter.nih.gov |
| A New Approach to an Old Problem: Redesigning Latent Tuberculosis Screening and Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,126,853 | March 17, 2020 | February 28, 2026 | TARTOF, SARA | reporter.nih.gov |
| Optimizing anti-microbial immunity by targeting Sts-1 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,125,627 | July 23, 2025 | June 30, 2029 | CARPINO, NICHOLAS A | reporter.nih.gov |
| Optimizing CDPK1 inhibitors for chronic toxoplasmosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,122,353 | March 1, 2022 | February 28, 2027 | SIBLEY, L. DAVID | reporter.nih.gov |
| Brain pathophysiology in SARS-CoV-2 disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,121,854 | July 1, 2021 | April 30, 2027 | SANDBERG, KATHRYN L | reporter.nih.gov |
| The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratios | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,121,386 | July 18, 2024 | June 30, 2029 | LUETKEMEYER, ANNE FREY | reporter.nih.gov |
| Tailored Behavioral Intervention to Prevent Household and Community Spread of COVID-19 among Latinos | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $3,120,476 | June 10, 2021 | February 28, 2027 | CRESPO, NOE CUAUHTEMOC | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| New York University School of Medicine | New York, NY | 41 | $732 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 49 | $618 million | 0 | $0 |
| Duke University | Durham, NC | 73 | $324.5 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 104 | $290.1 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 12 | $267.2 million | 0 | $0 |
| Emory University | Atlanta, GA | 94 | $244.4 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 62 | $241.3 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 16 | $206 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 86 | $191 million | 0 | $0 |
| University of Washington | Seattle, WA | 104 | $178.5 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 44 | $171.5 million | 0 | $0 |
| Washington University | Saint Louis, MO | 100 | $156.2 million | 0 | $0 |
| The Emmes Company, LLC | Rockville, MD | 1 | $150.3 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 22 | $146.5 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 84 | $145.5 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 20 | $144.3 million | 0 | $0 |
| Technical Resources International, Inc. | Bethesda, MD | 2 | $134.8 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 54 | $133.1 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 76 | $131 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 42 | $116.4 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 66 | $113.9 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 86 | $112.3 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 28 | $103.1 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 4 | $94.5 million | 0 | $0 |
| University of Chicago | Chicago, IL | 37 | $94.5 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 54 | $89.9 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 50 | $89.1 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 64 | $87.5 million | 0 | $0 |
| Yale University | New Haven, CT | 73 | $87 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 53 | $85.3 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 51 | $85 million | 0 | $0 |
| Sri International | Menlo Park, CA | 6 | $83.8 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 53 | $80.1 million | 0 | $0 |
| American Type Culture Collection | Manassas, VA | 4 | $77.6 million | 0 | $0 |
| Stanford University | Stanford, CA | 53 | $74.3 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 36 | $70.1 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 52 | $68.2 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 43 | $67.8 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 42 | $59.5 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 40 | $59 million | 0 | $0 |
| University of California at Davis | Davis, CA | 55 | $58.4 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 36 | $58.1 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 50 | $57 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 29 | $55.3 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 35 | $54.9 million | 0 | $0 |
| Ohio State University | Columbus, OH | 43 | $53.6 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 54 | $53.2 million | 0 | $0 |
| Venatorx Pharmaceuticals, Inc. | Malvern, PA | 8 | $51.7 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 24 | $51.3 million | 0 | $0 |
| Colorado State University | Fort Collins, CO | 32 | $49.5 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 34 | $48 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 12 | $47.8 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 35 | $47.4 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 17 | $45.6 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 29 | $42.1 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 21 | $41.9 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 32 | $40.9 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 18 | $40.8 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 39 | $39.4 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 23 | $38.3 million | 0 | $0 |
| Revagenix, Inc. | San Mateo, CA | 2 | $37.2 million | 0 | $0 |
| University of Florida | Gainesville, FL | 34 | $37 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 27 | $36.8 million | 0 | $0 |
| University of Rochester | Rochester, NY | 20 | $36.6 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 20 | $36.4 million | 0 | $0 |
| Rockefeller University | New York, NY | 16 | $35.9 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 36 | $34.4 million | 0 | $0 |
| Crestone, Inc. | Boulder, CO | 3 | $32.5 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 23 | $32.3 million | 0 | $0 |
| Battelle Memorial Institute | Columbus, OH | 4 | $31.4 million | 0 | $0 |
| Wits Health Consortium (pty), LTD | Parktown | 4 | $30.4 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 22 | $29.8 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 8 | $29.7 million | 0 | $0 |
| University of New Mexico Health Scis CTR | Albuquerque, NM | 8 | $29 million | 0 | $0 |
| Henry M. Jackson FDN for the Adv Mil/med | Bethesda, MD | 15 | $28.6 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 11 | $27.6 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 15 | $27.1 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 15 | $26.2 million | 0 | $0 |
| Texas Biomedical Research Institute | San Antonio, TX | 18 | $25.9 million | 0 | $0 |
| University of Montana | Missoula, MT | 4 | $25.9 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 17 | $25.9 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 26 | $25.8 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 9 | $25.6 million | 0 | $0 |
| Cornell University | Ithaca, NY | 22 | $25.5 million | 0 | $0 |
| LSU Pennington Biomedical Research CTR | Baton Rouge, LA | 1 | $25.5 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 7 | $25.4 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 17 | $24.8 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 12 | $24.6 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 20 | $24.2 million | 0 | $0 |
| Hackensack University Medical Center | Hackensack, NJ | 10 | $23.8 million | 0 | $0 |
| University of Cape Town | Rondebosch | 10 | $23.8 million | 0 | $0 |
| Access to Advanced Health Institute | Seattle, WA | 3 | $23.5 million | 0 | $0 |
| Broad Institute, Inc. | Cambridge, MA | 8 | $23.2 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 15 | $23 million | 0 | $0 |
| Digital Infuzion, Inc. | Rockville, MD | 2 | $22.8 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 20 | $22.3 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 17 | $22 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 18 | $21.4 million | 0 | $0 |
| Stellenbosch University | Stellenbosch | 13 | $20.7 million | 0 | $0 |
| University of Vermont & ST Agric College | Burlington, VT | 17 | $20.4 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 2,820 | $2,022,291,726 | 0 | $0 |
| 2024 | 2,984 | $2,206,521,572 | 0 | $0 |
| 2023 | 3,026 | $2,354,929,186 | 0 | $0 |
| 2022 | 2,097 | $2,065,151,413 | 0 | $0 |
| 2021 | 1,367 | $1,938,481,098 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 27 awards here | |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 15 awards here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) | PA-24-182 | NIH | May 8, 2027 | Not listed | Notice number printed on 8 awards here | |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | May 7, 2027 | Not listed | Notice number printed on 4 awards here | |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed) | PA-24-188 | NIH | May 7, 2027 | Not listed | Notice number printed on 3 awards here | |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | May 7, 2027 | Not listed | Notice number printed on 2 awards here | |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required) | PA-24-184 | NIH | May 8, 2027 | Not listed | Notice number printed on 2 awards here | |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | December 3, 2026 | Not listed | Notice number printed on 2 awards here | |
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | December 3, 2026 | Not listed | Notice number printed on 1 award here | |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) | PA-25-304 | NIH | January 7, 2028 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 3,325 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 3,325 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 3,325 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 3,325 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 3,325 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 3,325 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 3,325 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 3,325 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 3,325 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 3,325 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.